NHS to Introduce First Licensed Treatment for Vitiligo Across England
A groundbreaking cream offering new hope to more than 80,000 individuals in England living with vitiligo has received approval for NHS use. This marks the first licensed treatment specifically for this chronic skin condition to be recommended for patients.
Understanding Vitiligo and Its Impact
Vitiligo is a condition characterised by the development of white patches on the skin, resulting from the immune system attacking pigment-producing cells that give skin its colour. Approximately one in every 100 people in the UK is estimated to live with vitiligo, which can affect any area of the body but typically appears on the face, neck, hands, and skin creases.
There are two primary types: non-segmental vitiligo, where patches appear symmetrically on both sides of the body, and segmental vitiligo, where patches are confined to one specific area. The condition often carries significant psychological, social, and medical burdens for those affected.
Details of the New Treatment
The treatment, ruxolitinib, marketed under the brand name Opzelura, has been given the green light by the National Institute for Health and Care Excellence (Nice). It is recommended for patients aged 12 and over with non-segmental vitiligo affecting the face, particularly when other topical first-line treatments have proven ineffective or unsuitable.
Applied twice daily, the cream works by calming the immune system's attack on pigment cells, allowing skin cells to repair themselves and gradually regain their natural colour. Clinical trials have shown that patients using ruxolitinib were four times more likely to have facial skin restored to its natural colour compared to those on a placebo.
Expert and Patient Reactions
Helen Knight, director of medicines evaluation at Nice, emphasised the profound impact of facial vitiligo on quality of life, stating that this approval represents a welcome development for thousands. Professor Meghana Pandit, national medical director at NHS England, noted that while the treatment may not suit everyone, it could make a profound difference for many individuals.
Patient advocate Pav Korpal shared a personal perspective, highlighting the visibility of vitiligo on brown skin and the bullying and anxiety it can cause. Korpal expressed renewed optimism, noting that treating physical symptoms can also help manage psychological effects.
Abigail Hurrell, chief executive of The Vitiligo Society, described the approval as a historic milestone that acknowledges the condition's significant impact and marks a shift toward equitable care. Similarly, Emma Rush of Vitiligo Support UK called it an important landmark, praising Nice for listening to patient evidence.
Implementation and Availability
NHS England is expected to make ruxolitinib cream available within three months following the publication of Nice's final guidance. Patients have reported that the cream is less time-consuming than light therapy, which typically requires hospital visits, offering a more convenient and effective treatment option.
This development is set to transform care for vitiligo patients, providing a licensed, accessible treatment that addresses both the physical and emotional challenges of the condition.
